CCL2 and pancreatic ductal adenocarcinoma: Overall, our findings are supported by a recent publication from Kalbasi et. al., showing an RT-specific increase in the production of CCL2 by tumor cells in pancreatic ductal adenocarcinoma models, and an increased efficacy of RT when this chemokine is depleted [52].